Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation.
AML
MRD
biomarkers
cytogenetics and molecular markers
multiparametric flow cytometry
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
03 Mar 2021
03 Mar 2021
Historique:
received:
10
01
2021
revised:
11
02
2021
accepted:
24
02
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Measurable residual disease (MRD) is increasingly employed as a biomarker of quality of complete remission (CR) in intensively treated acute myeloid leukemia (AML) patients. We evaluated if a MRD-driven transplant policy improved outcome as compared to a policy solely relying on a familiar donor availability. High-risk patients (adverse karyotype, FLT3-ITD) received allogeneic hematopoietic cell transplant (alloHCT) whereas for intermediate and low risk ones (CBF-AML and NPM1-mutated), alloHCT or autologous SCT was delivered depending on the post-consolidation measurable residual disease (MRD) status, as assessed by flow cytometry. For comparison, we analyzed a matched historical cohort of patients in whom alloHCT was delivered based on the sole availability of a matched sibling donor. Ten-years overall and disease-free survival were longer in the MRD-driven cohort as compared to the historical cohort (47.7% vs. 28.7%,
Identifiants
pubmed: 33802502
pii: cancers13051083
doi: 10.3390/cancers13051083
pmc: PMC7959451
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Expert Rev Hematol. 2018 Apr;11(4):307-313
pubmed: 29495904
JAMA. 2009 Jun 10;301(22):2349-61
pubmed: 19509382
Leukemia. 2019 Nov;33(11):2599-2609
pubmed: 31073153
Lancet Oncol. 2018 Dec;19(12):1668-1679
pubmed: 30442503
Blood. 2012 Jan 12;119(2):332-41
pubmed: 22039260
Blood. 2014 Nov 27;124(23):3345-55
pubmed: 25049280
J Clin Oncol. 2017 Jan 10;35(2):185-193
pubmed: 28056203
J Clin Oncol. 2018 May 20;36(15):1486-1497
pubmed: 29601212
Blood. 2010 Jul 22;116(3):354-65
pubmed: 20385793
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Blood. 2019 Sep 19;134(12):935-945
pubmed: 31395600
Leukemia. 2020 Jun;34(6):1577-1587
pubmed: 31974434
J Clin Oncol. 2008 Oct 20;26(30):4944-51
pubmed: 18606980
Cytometry B Clin Cytom. 2013 Oct 5;:
pubmed: 24123710
Leukemia. 2006 Oct;20(10):1783-9
pubmed: 16838027
Blood. 2003 Aug 15;102(4):1232-40
pubmed: 12714526
Haematologica. 2017 May;102(5):865-873
pubmed: 28126965
Blood. 2000 Dec 1;96(12):3948-52
pubmed: 11090082
Blood. 2012 Jul 12;120(2):468-72
pubmed: 22517895
Blood. 2013 May 16;121(20):4056-62
pubmed: 23535063
Best Pract Res Clin Haematol. 2008 Mar;21(1):85-92
pubmed: 18342816
J Clin Oncol. 2016 Jul 20;34(21):2557-8
pubmed: 27185839
Nat Rev Clin Oncol. 2012 Oct;9(10):579-90
pubmed: 22949046
Leukemia. 2003 Nov;17(11):2178-82
pubmed: 14576731
Am J Hematol. 2018 Oct;93(10):1267-1291
pubmed: 30328165
Best Pract Res Clin Haematol. 2015 Jun-Sep;28(2-3):133-40
pubmed: 26590770
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
J Clin Oncol. 2003 Dec 15;21(24):4642-9
pubmed: 14673054
Curr Opin Hematol. 2017 Mar;24(2):132-138
pubmed: 27930388
Biometrics. 1978 Dec;34(4):541-54
pubmed: 373811
J Clin Oncol. 2014 Jan 20;32(3):219-28
pubmed: 24297940
Blood. 2010 Sep 30;116(13):2295-303
pubmed: 20548095
Bone Marrow Transplant. 2017 Mar;52(3):473-475
pubmed: 27941782
J Clin Oncol. 2009 Nov 10;27(32):5397-403
pubmed: 19826132